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GENERAL COMMENTS
Authors have tried to address the treatment outcome and safety of DAAs in chronic hepatitis C patients with HCC and compared to those without HCC. Manuscript was nicely written. Results address the research question. Major adverse events and treatment discontinuation with current DAA therapy are rare. Authors reported treatment discontinuation and serious adverse events, more than 10% in patients with HCC. Most of the serious adverse events may be related with use of Ribavirin rather than DAAs. Authors can report these serious adverse events and treatment discontinuation with specific treatment regimen that would clarify whether these are in fact related to DAAs or ribavirin related. Authors have tried to address the treatment outcome and safety of DAAs in chronic hepatitis C patients with HCC and compared to those without HCC. Manuscript was nicely written. Results address the research question. Major adverse events and treatment discontinuation with current DAA therapy are rare. Authors reported treatment discontinuation and serious adverse events, more than 10% in patients with HCC. Most of the serious adverse events may be related with use of Ribavirin rather than DAAs. Authors can report these serious adverse events and treatment discontinuation with specific treatment regimen that would clarify whether these are in fact related to DAAs or ribavirin related.
REVIEWER
Reply: Thank for comment. The rate of serious adverse events did not differ between patients with or without ribavirin use (2.4 % vs. 1.3 %, P=0.29). By contrast, patients with ribavirin use had a higher rate of early discontinuation than those without (6.6 % vs.2.2 %, P=0.005). However, patients with viable HCC did not have higher proportion of RBV use compared to those without viable HCC (18.4 % vs, 23.6 %, P=0.47), indicating that RBV may not be the main reason for higher early discontinuation in the population. As for the DAA regimens, rates of SAE (1.2 % vs. 2.7 %, P=0.25) or early treatment termination (2.7 % vs. 5.4 %, P=0.12) did not differ between patients with or with protease inhibitor (asunaprevir, paritaprevir or grazoprevir). We have address it in the revised manuscript.
Reviewer 2.
1. The number of patients in the active HCC group (n=38) is low and one additional SVR could have significantly changed the conclusions. This should be stated in the limitations.
Reply: Thanks for the comment. We have denoted it as the limitation in the revised text.
2. It is unclear why there was such a high rate of mortality in patients with active HCC. Do the authors attribute this to the treatments of HCC (decompensation after surgical resection or complications related to transplant) or are these related to treatment (worsening liver function in a Child B cirrhosis patient who received a Protease Inhibitor)? 15% of active HCC patients were Child B. Did any of these patients received PRoD or other PI based regimen? Additional information on SAEs in this population should be provided.
Reply: A high rate of mortality in patients with active HCC may due to relative small sample size. Actually, one 3 (0.4 %) patients expired in the overall population (two HCC patients with septic shock and liver failure; one non-HCC patient with variceal bleeding). All of them were not treatment regimens related. Protease inhibitors were contraindicated for patients with decompensated liver cirrhosis and none of our decompensated patients received PI-based regimens. We have depicted the SAEs one by one in the supplementary 
